Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients
Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients
复制标题
DOI：
10.2217/pgs.14.172
复制
发表时间：
2015-01-01
期刊：
影响因子：
2.1
通讯作者：
Potocnik, Uros
中科院分区：
文献类型：
--
作者：
Koder, Silvo;Repnik, Katja;Potocnik, Uros
目的：观察单核苷酸多态性是否有助于预测克罗恩病（CD）患者对阿达木单抗（ADA）生物治疗的反应。材料与方法：采用IBDQ指数和CRP水平监测治疗反应。我们对102名斯洛文尼亚CD患者的31个CD相关基因进行了基因分型。结果：ATG 16 L1 SNP rs 10210302与定义为CRP水平降低的治疗反应的最强相关性。在31个检测的CD相关基因（PTGER 4、CASP 9、IL 27、C11 orf 30、CCNY、IL 13、NR 1 I2）中，7个额外的SNP显示与ADA应答相关。结论：我们的研究结果表明，CD患者的ADA反应是由CD风险基因中的SNP遗传易感的，并表明ATG 16 L1是ADA治疗中最有希望的药物反应候选基因。原始提交日期：2014年9月24日;修订日期：2014年12月1日
Aim: To see if SNPs could help predict response to biological therapy using adalimumab (ADA) in Crohn's disease (CD). Materials & methods: IBDQ index and CRP levels were used to monitor therapy response. We genotyped 31 CD-associated genes in 102 Slovenian CD patients. Results: The strongest association for treatment response defined as decrease in CRP levels was found for ATG16L1 SNP rs10210302. Additional SNPs in 7 out of 31 tested CD-associated genes (PTGER4, CASP9, IL27, C11orf30, CCNY, IL13, NR1I2) showed suggestive association with ADA response. Conclusion: Our results suggest ADA response in CD patients is genetically predisposed by SNPs in CD risk genes and suggest ATG16L1 as most promising candidate gene for drug response in ADA treatment. Original submitted 24 September 2014; Revision submitted 1 December 2014